KFAS
RYTM icon

Keating Financial Advisory Services’s Rhythm Pharmaceuticals RYTM Stock Holding History

Keating Financial Advisory Services’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.89K Buy
35
+24
+218% +$2.17K ﹤0.01% 1672
2026
Q1 		$957 Buy
11
+2
+22% +$194 ﹤0.01% 2104
2025
Q4 		$963 Buy
+9
New +$955 ﹤0.01% 1817

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Keating Financial Advisory Services's RYTM Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Rhythm Pharmaceuticals (RYTM) stake by 218% in Q2 2026, buying an estimated $2.17K and bringing the position to 35 shares worth $3.89K. The position accounts for ﹤0.01% of the portfolio, ranked #1672.

Keating Financial Advisory Services first reported a position in RYTM in Q4 2025 and has held it in 3 quarters since. 305 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Keating Financial Advisory Services held 35 shares of Rhythm Pharmaceuticals worth $3.89K as of Q2 2026.
  • Keating Financial Advisory Services bought 24 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $2.17K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1672 holding.
  • Keating Financial Advisory Services first reported a position in Rhythm Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 305 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.